10-year follow-up shows no significant difference in all-cause death between PCI and CABG

Ten-year survival rates of the SYNTAX trial showed no significant difference in all-cause death between percutaneous coronary intervention (PCI) and drug-eluting stents vs coronary artery bypass grafting (CABG) in the overall cohort of patients with coronary artery disease (CAD). However, CABG vs PCI provided a significant survival benefit for patients with three-vessel disease, whereas no treatment difference was seen in all-cause death for patients with left main disease. The original SYNTAX trial included 1,800 patients with de novo three-vessel and/or left main CAD. Previously reported were 1-year and 5- year survival rates. The SYNTAX Extended survival study is he first and largest randomised trial reporting 10-year all-cause death after PCI with drug-eluting stents vs CABG in patients with three-vessel and left main disease [1]. Patients were randomised to PCI (n=841), trial) or CABG (n=848). This translates into 93.4% and 94.7%, respectivel...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 10 October, 2019